Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET

[D.ap]

5 In summary
In the last decade, the number of mAbs and TKI used in the treatment of NSCLC rapidly increased as a result of the identification of ever more critical tumor targets. PET using radiolabeled targeting mAbs and TKIs can provide an imaging biomarker for personalizing therapy.


http://www.sciencedirect.com/science/ar ... 0216303476